Renova Therapeutics, Inc.
Funding history
About Renova Therapeutics, Inc.
How much funding has Renova Therapeutics, Inc. raised?
Renova Therapeutics, Inc. has raised $167K in total funding. The most recent round was Series C.
Where is Renova Therapeutics, Inc. headquartered?
Renova Therapeutics, Inc. is headquartered in Carlsbad, CA.
What problem does Renova Therapeutics, Inc. solve?
Chronic diseases such as congestive heart failure and type 2 diabetes currently lack definitive, durable treatments.
What's Renova Therapeutics, Inc.'s solution?
Renova Therapeutics develops paracrine gene therapies (RT-100, an AC6 gene transfer, and RT-200, a Urocortin 2 gene transfer) intended to be single-dose, life-long treatments that restore heart and metabolic function.
What makes Renova Therapeutics, Inc. different?
The company points to its founders' nearly 50 combined years of pioneering gene therapy work, proprietary disease-mechanism insights, and UK MHRA Innovation Passport designations awarded to both RT-200 and AC6.
What makes Renova Therapeutics, Inc. notable?
Co-founder Dr. H. Kirk Hammond of UC San Diego previously co-founded Collateral Therapeutics; CEO and co-founder Jack W. Reich received an Entrepreneur of the Year award.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.